Marketing: Page 63
-
After criticism, Valeant details plans for hospital discounts on heart drugs
Although the company had promised discounts on Nitropress and Isuprel earlier this year, a Senate committee investigation found few hospitals had actually received any relief.
By Ned Pagliarulo • May 16, 2016 -
Regneron CEO counters criticism from ICER on pricing
The Boston-based Institute of Clinical and Economic Research (ICER) has become a prominent value-based-analysis think tank in Boston -- but not everyone is buying their claims.
By Nicole Gray • May 13, 2016 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Cigna signs value-based pricing deals with Amgen, Sanofi for PCSK9 drugs
Under the separate agreements, prices for the cholesterol-lowering drugs Repatha and Praluent will be linked to patient outcomes.
By Nicole Gray • May 12, 2016 -
Opko Health's quest to redefine treatment for secondary HPT
BioPharma Dive spoke to a pair of company executives about their strategy to address a major challenge faced by patients with chronic kidney disease.
By Nicole Gray • May 12, 2016 -
Colombian diplomat warns of fallout from Novartis patent battle
In a leaked memo, a Colombian official warned his government that U.S. support for a peace initiative could be harmed if Colombia issues a patent override for Novartis' Gleevec.
By Ned Pagliarulo • May 11, 2016 -
GSK's lupus drug finally wins NICE backing, but only after discounts
The British cost agency had rejected the drug in 2011 due to concerns over efficacy and price.
By Nicole Gray • May 11, 2016 -
Americans may have overspent billions on brand-name drugs, study finds
Increased therapeutic substitution by physicians would have sharply lowered costs in the two-year period studied, researchers said.
By Nicole Gray • May 11, 2016 -
India awards patent to Gilead's Sovaldi
Patient advocacy and humanitarian groups had opposed Gilead's efforts to win protection for the hepatitis C treatment, claiming a patent would hurt patient access to affordable generic copies.
By Ned Pagliarulo • May 10, 2016 -
FDA
FDA flags potential safety risk for Lilly antipsychotic drug
In rare cases, olanzapine can cause a serious, and sometimes fatal, skin reaction.
By Ned Pagliarulo • May 10, 2016 -
Wave Life Sciences touts more effective Duchenne drug
Just last week, Pfizer and Wave agreed to a potentially $911 million deal for advancing development of several genetic therapies for metabolic diseases.
By Nicole Gray • May 10, 2016 -
U.K. cost agency recommends new PCSK9 drugs, but only after further discounts
Amgen's Repatha, and Sanofi/Regeneron's Praluent have had disappointing launches so far, despite their efficacy in lowering cholesterol levels.
By Nicole Gray • May 9, 2016 -
ICER questions high prices of multiple myeloma meds
A number of new drugs have come onto the market recently, including Johnson & Johnson's Darzalex and Amgen's Kyprolis.
By Nicole Gray • May 9, 2016 -
Clovis shuts down cancer drug, will reduce staff by 35%
Last month, an FDA panel had overwhelmingly voted against recommending approval for Clovis' rociletinib.
By Nicole Gray • May 6, 2016 -
Regeneron reports strong Q1, but key drug faces pressure
PCSK9 drug Praluent generated only $13 million in Q1 sales—lower than the company had hoped.
By Nicole Gray • May 6, 2016 -
Elizabeth Regan/BioPharma Dive
New Zealand pushes back on coverage for Merck's Keytruda
Adding to Merck's challenges in the country, the cost agency Pharmac has proposed funding for rival Bristol-Myers' Opdivo.
By Nicole Gray • May 5, 2016 -
Bayer's Xarelto projected to become top-selling drug in Europe by 2022
Although Xarelto is an older drug, expanded indications and a new reversal agent could boost sales in Europe. Globally, however, the drug is predicted to fall well out of the top-ten drugs by sales.
By Nicole Gray • May 4, 2016 -
Israeli pharma company provides rare disease drug for free after it can't find patients
Taro Pharma developed Keveyis for the treatment of primary periodic paralysis, a condition estimated to affect 5,000 patients in the U.S., many of whom are undiagnosed.
By Ned Pagliarulo • May 3, 2016 -
How Aprecia Pharma hopes to tackle patient noncompliance with 3-D printed drug
Aprecia's seizure medication Spritam is the first 3-D printed drug to win FDA approval.
By Nicole Gray • May 3, 2016 -
Colombia reportedly set to override Novartis patent on a key cancer drug
So-called compulsory licenses allow generic drugmakers to manufacture a branded drug before its patent expires.
By Nicole Gray • May 3, 2016 -
FDA
Takeda renames antidepressant after name confusion leads to errors
Brintellix will now be marketed as Trintellix to distinguish it from AstraZeneca's Brilinta.
By Nicole Gray • May 3, 2016 -
Federal judge reopens high-stakes patent case between Merck and Gilead
Merck recently won $200 million in damages from Gilead after a federal jury upheld its patent claims tied to two hepatitis C drugs.
By Ned Pagliarulo • May 1, 2016 -
Crestor tumbles off patent cliff as first generic copy approved in US
AstraZeneca warned generic competition for the blockbuster cholesterol drug would likely hurt earnings in 2016.
By Nicole Gray • May 1, 2016 -
Canadian drugmaker tells CMS it can make cheaper version of cancer drug Xtandi
Made by Medivation and Astellas, Xtandi costs more than $129,000 per treatment in the U.S.
By Nicole Gray • April 29, 2016 -
Elizabeth Regan/BioPharma Dive
New Express Scripts program aims to react faster to spikes in drug prices
The major PBM also plans to expand indication-specific pricing for reimbursing drug costs.
By Nicole Gray • April 29, 2016 -
AstraZeneca debuts new tech along with approval of COPD inhaler
Bevespi will face a highly competitive U.S. respiratory market.
By Nicole Gray • April 27, 2016
Previous
